Dr. Stacey Ma has joined Elanco’s Board of Directors, effective immediately. Dr. Ma brings deep manufacturing and innovation expertise to the company, holding masters and doctorate degrees in chemical engineering and a bachelor’s in chemical engineering.
Elanco Animal Health Incorporated has announced the appointment of Dr. Stacey Ma to its Board of Directors, effective immediately. Dr. Ma brings extensive global leadership experience in biopharmaceutical development and manufacturing, further strengthening Elanco’s expertise in these critical areas, according to the company’s statement.
“We are delighted to add Stacey to the Elanco Board,” says Lawrence Kurzius, Chairman of the Elanco Board of Directors. “Her deep understanding of product development, Chemistry, Manufacturing and Controls (CMC) strategy, and technical operations, combined with her proven leadership in driving innovation will be a welcome addition in the board room.”
Dr. Stacey Ma currently serves as Executive Vice President, Pharmaceutical Development and Manufacturing at Gilead Sciences, Inc., where she is responsible for product and portfolio strategy, technical development, supply chain, quality, CMC regulatory, and manufacturing operations for Gilead’s small- and large-molecule pipeline. Prior to Gilead, she held leadership positions at Sana Biotechnology, Inc. and Genentech/Roche, including Global Head of Pharma Technical Innovation, Manufacturing, Science and Technology.
“I am honored to join the Elanco Board of Directors,” expresses Dr. Ma. “I am passionate about innovation and technical excellence in life sciences and look forward to contributing to Elanco’s mission of improving the health and wellbeing of animals.”
Dr. Stacey Ma’s impressive career also includes significant contributions to the broader scientific community. She has co-chaired multiple international scientific conferences, served as an Associate Director of the Board of CASSS, and is a Fellow of the American Institute for Medical and Biological Engineering (AIMBE). She was recognized as one of the “Top 20 Women Leaders in Biopharma R&D” by Endpoints News in 2020.
“Stacey’s guidance will be highly valuable as Elanco’s Innovation, Portfolio and Productivity (IPP) strategy comes to life with our significant blockbuster potential products transitioning from research and regulatory to manufacturing scale up,” states Jeff Simmons, CEO at Elanco Animal Health. “Her drug development and CMC experience will also be beneficial as part of our Innovation, Science and Technology Committee as we develop our growing next generation pipeline to deliver a consistent flow of high-impact innovation.”
Dr. Ma holds masters and doctorate degrees in chemical engineering from Yale University and a bachelor’s in chemical engineering from the University of Minnesota.
